Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2005-001824-35-GB
EUCTR2005-001824-35-GB
Active, not recruiting
Phase 1

on-randomised phase II trial of Sequential Therapy of Imiquimod followed by Vaccination with TA CIN for High Grade VI

niversity of Manchester0 sites30 target enrollmentNovember 4, 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsVIN3
DrugsImiquimod

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
VIN3
Sponsor
niversity of Manchester
Enrollment
30
Status
Active, not recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 4, 2005
End Date
May 15, 2009
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
niversity of Manchester

Eligibility Criteria

Inclusion Criteria

  • •Aged 18\-70
  • •Non\-child bearing or using effective contraception
  • •Patients with VIN3 or AIN3, histologically confirmed by biopsy within the previous 3 months
  • •Given written informed consent
  • •Patients must have at least one lesion of sufficient size to allow biopsies to be taken on 3 occasions and for disease evaluation to be performed. (It is estimated that a lesion of approximately 1 cm diameter would be sufficient.)
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • •Any patient who has received active treatment for VIN3 or AIN3 in the previous 4 weeks prior to enrolment.
  • •Any patient with VAIN3 requiring treatment
  • •Any patient who has received an HPV vaccine in the past
  • •Known immunodeficiency, defined as:
  • •Active eczema in the last 12 months
  • •Any patient who is pregnant, planning pregnancy, or breast feeding
  • •Any patient receiving immunosuppressive therapy
  • •Any patient with clinically significant abnormal serum biochemistry, haematology or urinanalysis
  • •Any patient with evidence of an ongoing infection
  • •History of severe allergy including eczema or other exfoliative skin disorder or active skin diseases such as psoriasis, lichen planus or sepsis among patients or among close social, sexual or domestic contacts

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Phase II clinical trial of palliativ treatment of patients with advanced non-operable gastric carcinoma: FLOT regimen followed by AIO regimen and irinotecan combined with artificial nutrition and physical activity - impact on quality of life and fatigue: FLOTIRI gastric cancer trialAdvanced non-resectable adenocarcinoma of the stomach and the gastro-oesophageal junctionMedDRA version: 15.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2009-014895-23-DEniversitätsklinikum Erlangen50
Not yet recruiting
Not Applicable
Randomized Phase II study regarding treatment cycles of neo-adjuvant chemotherapy with biweekly triplet gemcitabine/cisplatin/s-1 for biliary tract cancerResectable Biliary Tract Cancers
JPRN-UMIN000036542KHBO100
Active, not recruiting
Not Applicable
Randommized Phase II study of the continuous treatment vs. standard treatment with capecitabine in metastatic breast cancer patientsMETASTATIC BREAST CANCERMedDRA version: 7.0Level: LLTClassification code 10027475
EUCTR2004-002759-15-ESDr. Miguel Martín
Active, not recruiting
Phase 1
Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC)
EUCTR2016-004452-29-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS70
Recruiting
Phase 1
Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC)metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)MedDRA version: 26.1Level: LLTClassification code: 10001198Term: Adenocarcinoma of the prostate metastatic Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]
CTIS2024-511660-89-00Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.70